Results 91 to 100 of about 24,752 (187)

Low‐dose X‐ray radiation induces an adaptive response: A potential countermeasure to galactic cosmic radiation exposure

open access: yesExperimental Physiology, EarlyView.
Abstract Space exploration involves many dangers including galactic cosmic radiation (GCR). This class of radiation includes high‐energy protons and heavy ionizing ions. NASA has defined GCR as a carcinogenic risk for long‐duration space missions. To date, no clear strategy has been developed to counter chronic GCR exposure.
Siena Edwards   +3 more
wiley   +1 more source

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management

open access: yesLiver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatitis delta virus (HDV) infection causes chronic hepatitis D (CHD), the most severe form of chronic viral hepatitis with a high risk of progression to advanced liver disease. Off‐label pegylated interferon alpha was the primary treatment option in Europe prior to the introduction of bulevirtide, a first‐in‐class HDV entry inhibitor.
Monica Radu   +11 more
wiley   +1 more source

Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

open access: yesHematological Oncology, Volume 44, Issue 4, July 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is a clinically and molecularly heterogeneous disease. PKMYT1, a G2/M cell cycle kinase, has been implicated in tumor progression in several cancers, but its role in CLL remains unclear. We evaluated PKMYT1 expression in primary CLL samples and analyzed associations with cytogenetic features and clinical ...
Elizabete Cristina Iseke Bispo   +6 more
wiley   +1 more source

RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Tumor initiation and progression depend on a supportive and highly heterogeneous tumor microenvironment (TME). RNA modifications regulate signaling pathways and cytokine networks that shape TME dynamics, facilitating interactions between cancer cells and noncancerous stromal cells, and ultimately promoting immune evasion and tumor progression ...
Qiwen Li   +3 more
wiley   +1 more source

Molecular Interplay of PARN and Telomerase: Tail Modifiers and Disease Implications

open access: yesWIREs RNA, Volume 17, Issue 4, July/August 2026.
Schematic representation of the molecular interplay between PARN, telomerase‐associated, and the involvement of p53 in regulating telomere maintenance and genome stability. The top panel shows how normal PARN levels are involved in regulating p53 levels and balanced telomerase activity through their regulatory interaction with TERC and TERRA, thus ...
Sujitha Felicitus   +5 more
wiley   +1 more source

Engineering Extracellular Vesicles for Anti‐Aging Therapy: Mechanisms, Applications, and Perspectives

open access: yesAging Cell, Volume 25, Issue 7, July 2026.
This review systematically elucidates the multifactorial anti‐aging mechanisms of extracellular vesicles (EVs). By bridging fundamental biology with advanced bioengineering, scalable manufacturing, and clinical translation, it establishes a comprehensive framework for developing next‐generation EVs‐based precision nanotherapeutics to combat systemic ...
Xian Huang   +6 more
wiley   +1 more source

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3173-3186, 15 June 2026.
What's new? Errors in DNA double‐strand break (DSB) repair can lead to mutations, chromosomal instability, and ultimately cancer. Inhibitor of DNA‐binding 3 (ID3), a transcriptional repressor, is crucial to promoting DSB repair and helping maintain genome stability. Here, the authors investigated ID3 regulation of DNA repair via chromatin accessibility
Giuditta Della Corte   +10 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, Volume 20, Issue 6, Page 1626-1642, June 2026.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

BMI‐1 modulation and trafficking during M phase in diffuse intrinsic pontine glioma

open access: yesFEBS Open Bio, Volume 16, Issue 6, Page 1213-1221, June 2026.
The schematic illustrates BMI‐1 phosphorylation during M phase, which triggers its translocation from the nucleus to the cytoplasm. In cycling cells, BMI‐1 functions within the PRC1 complex to mediate H2A K119 monoubiquitination. Following PTC596‐induced M phase arrest, phosphorylated BMI‐1 dissociates from PRC1 and is exported to the cytoplasm via its
Banlanjo Umaru   +6 more
wiley   +1 more source

Ultrasmall Platinum Nanoparticles for Radiation‐Enhanced Cancer Therapy

open access: yesAdvanced Functional Materials, Volume 36, Issue 45, 5 June 2026.
This work proposes a nanomedicine‐based strategy to enhance X‐ray radiotherapy for cancer treatment. Ultrasmall Pt‐NPs exhibit catalase‐like activity that may contribute to modulation of the tumor microenvironment and amplify interactions between radiation and biological matter, leading to increased DNA damage.
Miguel Encinas‐Gimenez   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy